Physician profile
Michael Bashevkin
NPI 1588664213
$1,685.28
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $638 · 2021: $130 · 2022: $18.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $303.21 | 2019-2021 | |
| Amgen INC. | $155.51 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $147.51 | 2019-2020 | |
| Pfizer INC. | $103.69 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.64 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.29 | 2019-2020 | |
| Janssen Biotech, INC. | $69.11 | 2019-2020 | |
| Genzyme Corporation | $67.56 | 2019-2021 | |
| Clovis Oncology, INC. | $63.90 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.98 | 2019-2020 | |
| Seagen INC. | $40.66 | 2020 | |
| Daiichi Sankyo INC. | $39.37 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $38.82 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $38.08 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $35.21 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.94 | 2020 | |
| Puma Biotechnology, INC. | $30.09 | 2019 | |
| Gilead Sciences, INC. | $28.59 | 2019-2021 | |
| Tesaro, INC. | $26.64 | 2019 | |
| Lilly USA, LLC | $25.00 | 2020 | |
| Jazz Pharmaceuticals INC. | $24.84 | 2020 | |
| Pharmacosmos Therapeutics INC. | $22.74 | 2021 | |
| Shire North American Group INC | $22.14 | 2019 | |
| Amag Pharmaceuticals, INC. | $21.12 | 2020 | |
| Acceleron Pharma, INC. | $20.71 | 2020 | |
| Sun Pharmaceutical Industries INC. | $18.42 | 2020 | |
| Ge Healthcare | $18.20 | 2022 | |
| Coherus Oncology, INC. | $18.06 | 2020 | |
| Glaxosmithkline, LLC. | $17.41 | 2021 | |
| Karyopharm Therapeutics INC. | $17.27 | 2020 | |
| Incyte Corporation | $14.43 | 2019 | |
| Dendreon Pharmaceuticals LLC | $13.46 | 2019 | |
| Dova Pharmaceuticals | $11.68 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bashevkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.